The CITRELOCK DUO fixation device for biceps tenodesis. Credit: Acuitive Technologies/ GlobeNewswire.

Acuitive Technologies has received 510(k) clearance from the US Food and Drug Administration (FDA) for its CITRELOCK DUO fixation device for biceps tenodesis.

The new sports medicine fixation device offers surgeons a differentiated design through a tendon-friendly spiral thread featuring the Citregen next-generation resorbable technology.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Citregen has advanced molecular and mechanical properties for orthopaedic surgical applications.

The new device consists of a biomimetic material composition for matching the native bone inorganic content as well as a soft spiral thread design for eliminating tendon laceration.

Featuring elastomeric properties for enhanced pull-out strength, it also provides compressive strength like cortical bone and a modulus similar to trabecular bone.

See Also:

In addition, Citrelock duo delivers a controlled resorption rate to alleviate chronic inflammation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Acuitive product development vice-president Rui Ferreira said: “Our customers are looking for a fixation device with unique mechanical properties that protects the tendon’s integrity during insertion while providing improved fixation within the bone tunnel.

“Additionally, the Citrelock duo provides more predictable resorption while avoiding the chronic inflammation reported with other biodegradable polymers.

“With its innovative Citregen material technology and unique thread design, the Citrelock duo fills the clinical need surgeons have been seeking.”

Acuitive is focused on the development of advanced biomaterials and orthopaedic devices that participate in the natural musculoskeletal tissues’ healing process and address the shortcomings of existing biomaterials.